NMN (Nicotinamide Mononucleotide)
N-M-N (nik-oh-TIN-a-mide MON-oh-NUE-klee-oh-tide)
IUPAC beta-Nicotinamide mononucleotide
SMILES
C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)[O-])O)O)C(=O)N
D+
38.5/100
Evidence Summary
NMN is among the most popular longevity supplements, but its evidence grade is D+ — reflecting a significant gap between consumer enthusiasm and published clinical evidence.
Human trials to date are small (typically 30-80 participants), short-term (8-12 weeks), and use surrogate biomarkers rather than hard clinical endpoints. NMN reliably raises blood NAD+ levels, but no published RCT has demonstrated that this translates to measurable health outcomes in humans.
Regulatory status is unsettled: the FDA's drug preclusion determination was reversed in 2024, but the legal framework remains ambiguous. No NMN product carries USP Verified certification.
Human trials to date are small (typically 30-80 participants), short-term (8-12 weeks), and use surrogate biomarkers rather than hard clinical endpoints. NMN reliably raises blood NAD+ levels, but no published RCT has demonstrated that this translates to measurable health outcomes in humans.
Regulatory status is unsettled: the FDA's drug preclusion determination was reversed in 2024, but the legal framework remains ambiguous. No NMN product carries USP Verified certification.
Safety Considerations
Generally well-tolerated in short-term trials. Theoretical concern about NAD+ elevation fueling tumor metabolism in individuals with existing cancers. Long-term safety data absent. Regulatory status unsettled — FDA enforcement discretion, not formal approval as dietary supplement. Product quality varies enormously across 200+ brands.
Evidence Signals (0)
Known Interactions (1)
Products Containing NMN (Nicotinamide Mononucleotide)
No commercial products are currently listed for this molecule.
Regulatory Intelligence
This evidence profile reflects publicly available research as of March 15, 2026. Evidence grades may change as new research is published. ClinEvident grades the quality of published evidence — it does not evaluate the efficacy of any specific commercial product.